Shingrix in Solid Tumor Patients on Chemotherapy

• GSK1437173A Group

  Shingrix Vaccine (2 doses)

• Placebo Group

  Placebo (2 doses)

Primary

• Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo GroupsMonth 2

• Anti-Varicella Zoster Virus (VZV) gE Antibody ConcentrationsMonth 2

• Number of Subjects With Any and Grade 3 Solicited Local SymptomsDays 0-6 post-vaccination

• Number of Days With Solicited Local SymptomsDays 0-6 post-vaccination

• Number of Subjects With Any, Grade 3 and Related Solicited General SymptomsDays 0-6 post-vaccination

Secondary

• Anti-VZV gE Antibody ConcentrationsMonth 13

• Number of Subjects With Vaccine Responses for Anti-gE Antibody ELISA ConcentrationsMonth 13

• Descriptive Statistics of the Frequency of gE-specific CD4[2+] T-cells in PreChemo GroupsMonth 13

• Number of Subjects With Vaccine Responses for gE-specific CD4[2+] T-cells in PreChemo GroupsMonth 13

• Number of Subjects With Serious Adverse Events (SAEs)From 30 days post last vaccination to Month 13

• Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs)From 30 days post last vaccination to Month 13